Cover Image

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Objectives: Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals vs non-black individuals. HCV trials submitted to the Food and Drug Administration (2013-2017) to support appr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kimberly Struble (Author), Kirk Chan-Tack (Author), Karen Qi (Author), Thamban Valappil (Author), Sarah Connelly (Author), Poonam Mishra (Author), Dionne Price (Author), Jeffrey Murray (Author), Debra Birnkrant (Author)
Format:	Book
Published:	Elsevier, 2019-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022)

Virological Mechanisms in the Coinfection between HIV and HCV
by: Maria Carla Liberto, et al.
Published: (2015)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
by: Borba HHL, et al.
Published: (2017)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
by: S Muhammed Shahanas, et al.
Published: (2024)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017)

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
by: Emma Gray, et al.
Published: (2017)

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
by: Fred Poordad, et al.
Published: (2017)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
by: Nicola Imperatore, et al.
Published: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
by: Saima Mushtaq, et al.
Published: (2022)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
by: Grenda Leite Pereira, et al.
Published: (2019)

Determination of HCV Genotypes in Iranian Isolates by PCR-RFLP
by: MH Ahmadi Pour, et al.
Published: (2006)

Genotyping Pattern Among Iranian HCV Positive Patients
by: A Sarafnejad, et al.
Published: (2010)

Genotyping Pattern among Iranian HCV Positive Patients
by: M Hajia, et al.
Published: (2010)

Determination of HCV Genotypes in Iranian Isolates by PCR-RFLP
by: MH Ahmadi Pour, et al.
Published: (2006)

Direct action antivirals are effective in the total eradication of HCV in renal transplants
by: Teresa Olea, et al.
Published: (2019)

Antiviral therapy of HCV-cirrhosis: case of sequential treatment and review of literature
by: Kakharman Yesmembetov, et al.
Published: (2018)

Hepatitis C Virus Infection and HCV Genotypes of Hemodialysis Patients
by: K Samimi-rad, et al.
Published: (2008)

Hepatitis C Virus Infection and HCV Genotypes of Hemodialysis Patients
by: K Samimi-rad, et al.
Published: (2008)

Biological hepatic markers of inflammation and fibrosis following durable sustained virological response to direct acting antiviral agents in HIV/HCV co-infected patients: preliminary results from the cohort driven by the CoReVIH at the University-Hospital of Clermont-Ferrand, France
by: Guillaume Laurichesse, et al.
Published: (2018)

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
by: Sarah R. Donaldson, et al.
Published: (2022)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020)

Impact of HCV antiviral therapy on the Liver Transplantation Waiting-List assessed by mathematical models
by: Eleazar Chaib, et al.
Published: (2019)

SCORING MODELS FOR PREDICTING HEPATOCELLULAR CARCINOMA RISK IN HCV PATIENTS AFTER ANTIVIRAL THERAPY
by: Oana Irina Gavril, et al.
Published: (2023)

Identification of the Genotypes Circulating in the Ecuadorian Population Infected with the Hepatitis C Virus (HCV)
by: Moncayo M, et al.
Published: (2023)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
by: Mario Enrico Canonico, et al.
Published: (2022)

The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine
by: Cristina Stasi, et al.
Published: (2016)

Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy
by: Yakoot M, et al.
Published: (2016)

Molecular Virology
Published: (2012)

Better design leads to better results - Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
by: Getu Zhaori, et al.
Published: (2023)

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
by: Ruochan Chen, et al.
Published: (2023)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals
by: Zachary C. Rich, et al.
Published: (2016)

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
by: Evi B. Struble, et al.
Published: (2023)

Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, CanadaResearch in context
by: Dahn Jeong, et al.
Published: (2024)

Prevalence of HCV infection and prevalent genotypes of HCV among drug users in Inner Mongolia Autonomous Region, 2022: a sentinel surveillance-based cross-sectional survey
by: Huai ZHANG, et al.
Published: (2024)

<it>PNPLA 3</it> I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
by: Rembeck Karolina, et al.
Published: (2012)

Viral genotype and HLA class II alleles influence on extra-hepatic manifestations of chronic HCV infection
by: M. Galeazzi, et al.
Published: (2011)

HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels
by: Maria Rendina, et al.
Published: (2022)

An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs
by: Adita Ayu Permanasari, et al.
Published: (2021)